Drug Index

Ledipasvir/Sofosbuvir

 
print

Mechanism :

Ledipasvir inhibits the HCV NS5A protein necessary for viral replication.
Sofosbuvir is a prodrug converted to its pharmacologically active form (GS-461203), inhibits NS5B RNA-dependent RNA polymerase, also essential for viral replication, and acts as a chain terminator.


Indication :

• Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection in combination with ribavirin.


Contraindications :

Hypersensitivity to any component of the formulation.


Dosing :

Children and Adolescents ≥12 years or weighing ≥35 kg: Available as ledipasvir 90 mg/sofosbuvir 400 mg tablet.

Chronic hepatitis C infection:

1 tablet orally once daily. Give for 12 weeks in genotype 1,4,5 and 6 and for 24 weeks in genotype 1 who are treatment experienced.


Adverse Effect :

Headache, fatigue, weakness, irritability, insomnia, dizziness, depression, nausea, increased serum lipase, hyperbilirubinemia, myalgia, increased creatine phosphokinase, cough, dyspnea.


Interaction :

Amiodarone: Sofosbuvir may enhance the bradycardic effect of Amiodarone.
Antacids: May decrease the serum concentration of Ledipasvir.
Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine.
Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.
P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Sofosbuvir and Ledipasvir.
Phenobarbital, Primidone, Rifabutin: May decrease the serum concentration of Sofosbuvir and Ledipasvir.


07/14/2019 20:00:14 Ledipasvir/Sofosbuvir
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0